Ridgeline Discovery
Lisa Christina Wellinger is an accomplished Senior Scientist at Ridgeline Discovery, with prior experience as a Scientist at Roche. Wellinger's academic journey includes a PhD candidacy at Roche and multiple research roles, including a Research Abroad Student position at Peter MacCallum Cancer Centre. Contributions to scientific research include a Master Thesis focusing on the sensitivity of c-Myc-driven tumors and a Bachelor Thesis on mRNA localization factors in Drosophila. Educational qualifications comprise a Master of Science and Bachelor of Science in Biochemistry from the University of Tübingen. Additional internship experiences span prestigious institutions like the Weizmann Institute of Science and the Max Planck Institute for Developmental Biology.
Previous companies
This person is not in any offices
Ridgeline Discovery
Ridgeline Discovery, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry and leading academics across Europe. In recent years, Ridgeline has assembled an international team of >50 highly experienced drug discovery professionals and built and operated several new successful companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics and Monte Rosa Therapeutics (NASDAQ: GLUE). Ridgeline is currently expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy with focus on oncology and immunology.